# Omalizumab to Accelerate a Symptom-driven Multi-food OIT

> **NCT04045301** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Philippe Bégin** · enrollment: 90 (actual)

## Conditions studied

- Food IgE-mediated Allergy
- Immunotherapy
- Omalizumab
- Physiological Effects of Drugs

## Interventions

- **BIOLOGICAL:** Omalizumab 16mg/kg
- **BIOLOGICAL:** Omalizumab 8mg/kg
- **BIOLOGICAL:** Placebo
- **OTHER:** Multi-food oral immunotherapy (OIT)

## Key facts

- **NCT ID:** NCT04045301
- **Lead sponsor:** Philippe Bégin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-11
- **Primary completion:** 2025-12
- **Final completion:** 2026-03
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-11-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04045301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04045301, "Omalizumab to Accelerate a Symptom-driven Multi-food OIT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04045301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*